Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on LinkedIn:
“With the development of novel PRMT 5 inhibitors, MTAP deficiency has become an important target to be exploited through Synthetic Lethality.
Had the opportunity to discuss this at an educational session dedicated to Rare Thoracic Cancers during ESMO Rare Cancers 26. Happy to share some key slides and takeaways.”
Other articles featuring Herbert Loong on OncoDaily.
